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Edited by Laszlo NagyAbstract The eﬀect of oxLDL on CD36 expression has been
assessed in preadipocytes induced to diﬀerentiate. Novel evidence
is provided that oxLDL induce a peroxisome proliferator-acti-
vated receptor c-independent CD36 overexpression, by up-regu-
lating nuclear factor erythroid 2 (NF-E2)-related factor 2
(Nrf2). The nuclear translocation of Nrf2 appeared to depend
on PKC pathway activation. In adipocytes, the CD36 up-regula-
tion may indicate a compensation mechanism to meet the de-
mand of excess oxLDL and oxidised lipids in blood, reducing
the risk of atherogenesis. Besides strengthening the hypothesis
that oxLDL can contribute to the onset of insulin-resistance,
data herein presented highlight the signiﬁcance of oxLDL-in-
duced CD36 overexpression within the cellular defence response.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Oxidised low-density lipoproteins (oxLDL) have been found
in atherosclerosis, type-2 diabetes, and recently in the plasma
of obese patients [1,2]. Several lines of evidence have demon-
strated that oxLDL play a crucial role in the pathogenesis of
atherosclerosis [3] and modulate growth, transcription factor
and cytokine expression, inﬂuencing cell activities [4,5]. We
have recently demonstrated that oxLDL are taken up through
a speciﬁc, saturable process mediated by CD36, aﬀecting the
adipose tissue homeostasis by inhibiting the diﬀerentiation of
preadipocytes [6]. CD36, an ubiquitous membrane glycopro-
tein, recognizes a variety of ligands in addition to modiﬁed
lipoproteins [7,8] and serves as a fatty acid (FA) transporter
in muscle and adipocytes [9], representing a tract of the matureAbbreviations: PPAR, peroxisome proliferator-activated receptor;
DMIX, diﬀerentiation mixture; STS, staurosporine; Nrf2, nuclear
factor erythroid 2 (NF-E2)-related factor 2; 4-HNE, 4-hydroxynone-
nal; FA, fatty acids
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doi:10.1016/j.febslet.2008.05.029adipocyte phenotype [10]. It has recently been shown that
CD36 plays a role in disturbed FA handling as observed in
the metabolic syndrome and type 2 diabetes mellitus [11]. In-
creased CD36 expression has been demonstrated in monocytes
of diabetic patients [12] and in subcutaneous and visceral adi-
pose tissues in human obesity [13]. In macrophages, oxLDL
provoke an increase in CD36 expression likely through the
activation of peroxisome proliferator-activated receptor c
(PPARc) pathway [14,15], because a variety of oxLDL compo-
nents, functions, as PPARc ligands [14].
Another transcription factor, the nuclear factor erythroid 2
(NF-E2)-related factor 2 (Nrf2), has been shown to be in-
volved in CD36 induction in macrophages [16]. Phosphoryla-
tion, induced by several signal transcription pathways such
as MAPK, PKC and PI3K, seems to be a principal mechanism
in Nrf2 activation [17–19].
With this in mind, we investigated the possible eﬀects of
oxLDL on CD36 expression in conﬂuent 3T3-L1 preadipo-
cytes induced to diﬀerentiate by hormonal mixture. We
showed for the ﬁrst time that oxLDL increased CD36 expres-
sion, even though the diﬀerentiation process appeared strongly
delayed. We demonstrated that the observed CD36 up-regula-
tion was regulated by a PPARc-independent pathway which
involves Nrf2 activation.2. Materials and methods
2.1. Cell culture and diﬀerentiation protocol
Murine 3T3-L1 preadipocytes (American Cell Culture Collection)
were plated and cultured in Dulbeccos modiﬁed Eagles medium
(DMEM) supplemented with 10% fetal calf serum. At conﬂuence (day
0) the cells were induced to diﬀerentiate by diﬀerentiation mixture
(DMIX) as described elsewhere [6]. In a set of experiments the cells were
treated with dexamethasone to evaluate its role on Nrf2 expression.
2.2. Plasma LDL isolation and oxidation
LDL (1.019–1.063 g/ml) were isolated from pooled fresh plasma of
healthy volunteers as described elsewhere [6]. Protein content was mea-
sured by Lowrys method [20]. Native LDL (nLDL) were dialysed with
a centrifugal ﬁlter device (MW cut-oﬀ 5000) (Millipore, Bedford, MA)
at 4 C according to the manufacturers instructions. The nLDL were
oxidised by 20 lMCuSO4 for 18 h at 37 C. Oxidation was stopped by
the addition of 1 mmol/l EDTA. The degree of LDL oxidation was
assessed by determining the content of TBARs [21] and 4-hydro-
xynonenal (4-HNE) [22] which were, respectively, 45 ± 7
nmol malondialdehyde equiv./mg LDL protein (vs. 4 ± 0.3 nmol in
nLDL), and 5.2 ± 0.6 nmol/mg protein (not detectable in nLDL).blished by Elsevier B.V. All rights reserved.
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OxLDL were sterilized by a 0.22 lm membrane (Millipore Corpora-
tion, Bedford, MA) and incubated with the cells. After testing diﬀerent
oxLDL concentrations (25–200 mg protein/l), 50 mg protein/l was cho-
sen because of the complete absence of cytotoxicity as assessed by the
Neutral Red assay. Under all the experimental conditions described
below, diﬀerentiating 3T3-L1 cells, untreated or treated with nLDL
(50 mg/l), were used as controls. At conﬂuence oxLDL were added
to the cells together with DMIX, and maintained in the medium
throughout the experiment. In a set of experiments, speciﬁc kinase
inhibitors were added to the cells 30 min before DMIX at concentra-
tions that eﬀectively inhibited targeted pathways without any signs
of cytotoxicity (see ﬁgure legends for details). Speciﬁcally, stauro-
sporine (STS) (Sigma, St. Louis, MO, USA) against protein kinase C
(PKC); rottlerin (Sigma) against PKCd; PD98059 (BIOMOL, Plym-
outh Meeting, PA, USA) against ERK1/2; SB203580 (BIOMOL)
against p38; SP600125 against JNK; and LY294002 (BIOMOL)
against PI3K.
2.4. Total RNA extraction and RT-PCR analysis
Total RNA was isolated from 3T3-L1 cells with the TRIZOL re-
agent (Invitrogen-Life technologies, USA) as described elsewhere [6].
Quantitative real-time PCR (RTq-PCR) was performed with gene
speciﬁc TaqMan MGB probes and primers (Applied Biosystems) in
an ABI 7700 sequence detector (Applied Biosystems). CD36 (accession
no.: NM_007643) and endogenous control TBP (TATA-box binding
protein, accession no.: NM_013684) were purchased as pre-designed
assays (CD36: Mm00432403_m1; TBP: Mm00446973_m1). Probes
and primers for PPARc gene expression were also designed by and
purchased from Applied Biosystems. As all primers pairs lie on diﬀer-
ent exons, DNAse treatment was not necessary. All gene expression as-
says have a FAM reporter dye at 5 0 end of TaqMan MGB probe and
a non-ﬂuorescent quencher at the 3 0 end of the probe.
Expression of CD36 and PPARc genes were determined as the
amount of CD36 and PPARc mRNA relative to mRNA for TBP by
using the comparative CT method described in the ABI 7700 sequence
detection system, user bulletin #2.
2.5. Immunoblotting analysis
For immunoblotting determination of Nrf2 and PPARc, nuclear
protein extracts were prepared by Nuclear/Cytosol fractionation Kit
(Medical & Biological Laboratories, Watertown, LA, USA) according
to the manufacturers instructions. For CD36, PKC, PKCd, phosphor-
ylated-PKC and phosphorylated-PKCd analyses, whole cell extracts
were prepared: cells were collected and washed twice in ice-cold PBS,
resuspended in 50 ll 1% TRITON X (Sigma) with 2 mM Na3VO4
and 5 ll of a mixture of protease inhibitors (Sigma), and incubatedA
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Fig. 1. OxLDL eﬀects on CD36 expression in 3T3-L1 cells. OxLDL (50 m
diﬀerentiate, and maintained in the medium throughout the experimental per
evaluated by Western blot. Values are expressed as percentage with respec
reference for protein evaluation. Values are means ± S.E.M. (n = 3). *P 6 0
nativeLDL-treated cells (nLDL) within each time point considered.on ice for 20 min. Cells were centrifuged at 18000 · g for 10 min at
4 C. Supernatants, assessed for protein concentration [20], were used
for Western Blot analysis as previously described [6]. Immunoblotting
was carried out using antibodies that recognise Nrf2, PPARc, CD36,
PKC (Santa Cruz, Biotechnology Inc., CA, USA), phospho-PKC,
PKCd, or phospho-PKCd (Cell Signalling Technology Inc., MA,
USA). The blots were treated with appropriate secondary antibody
conjugated with horseradish peroxidase (Santa Cruz Biotechnology)
followed by ECL detection (Amersham Bio-sciences, UK). Densito-
metric analysis was performed with a molecular imager FX (Bio-
Rad, Hercules, CA).
2.6. siRNA transfection
Nfr2 expression was inhibited with Nfr2-directed siRNA reagents
(mouse Nfr2, siGENOME SMARTpool siRNA; Dharmacon, Lafay-
ette, CO, USA). Brieﬂy, pre-conﬂuent 3T3-L1 preadipocytes were
transfected with 100 nM of Nrf2-siRNA mixed with DharmaFECT3
transfection reagent (Dharmacon) in the absence of serum, according
to the manufacturers instructions. SiCONTROL non-targeting siR-
NA was used as negative control and introduced in the cells following
the same protocol. Twenty-four hours later, the cells were subjected to
the standard diﬀerentiation protocol in the presence of oxLDL. At var-
ious time points thereafter, nuclear protein and whole cell extracts were
prepared for Nrf2 and CD36 protein analysis, respectively.
2.7. Assessment of PPARc activity
PPARc activation was determined in nuclear extracts with the Tran-
sAM ELISA kit (Active Motif Europe Rixensart, Belgium) according
to manufacturers recommendations.3. Results
3.1. CD36 expression in 3T3-L1 cells induced to diﬀerentiate
In untreated or nLDL-treated cells induced to diﬀerentiate
by DMIX, the expression of CD36, as mRNA and protein,
progressively increased during the entire experimental period
reaching a 4.6-fold increase for mRNA (Fig. 1A) and a four-
fold increase for protein (Fig. 1B) on day 7 (P 6 0.01) with re-
spect to day 0 as a consequence of the progressive acquisition
of the mature adipocyte phenotype [11]. In DMIX-treated
cells, oxLDL induced a further strong up-regulation of
CD36 mRNA with respect to the time-matched controls, par-
ticularly on day 7 (4.3-fold; P 6 0.01) (Fig. 1A), despite theAPDH
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Fig. 2. OxLDL eﬀects on PPARc expression in 3T3-L1 cells. OxLDL
(50 mg protein/l) were added to conﬂuent preadipocytes (day 0)
induced to diﬀerentiate, and maintained in the medium throughout
the experimental period. (A) RTq-PCR determination of PPARc
mRNA. Values are means ± S.E.M. (n = 3). (B) Nuclear PPARc
protein evaluated by Western blot (n = 3). The antibody recognized
both PPARc isoforms, c1 and c2. A representative blot is shown.
Lamin B was the reference for protein evaluation. (C) Evaluation of
PPARc activity. Bars represent the means ± S.E.M. (n = 4). *P 6 0.05
oxLDL-treated cells (oxLDL) vs. untreated (CTR) or nativeLDL-
treated cells (nLDL) within each time point considered.
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Fig. 3. OxLDL eﬀects on Nrf2 nuclear levels in 3T3-L1 cells. Nuclear Nrf2 pr
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strated [6]. Similarly, oxLDL also induced a signiﬁcant up-reg-
ulation of CD36 protein on day 2 (2.3-fold; P 6 0.05) and day
5 (1.7-fold; P 6 0.05) with respect to the controls (Fig. 1B).
However, unlike mRNA, on day 7, the value of protein expres-
sion was comparable to that observed in controls. This diﬀer-
ence could depend on several reasons such as changes in the
eﬃciency of mRNA translation in time, and/or variations in
the halving time of the protein, and/or altered post-transla-
tional modiﬁcation.
3.2. Eﬀects of oxLDL on the expression and activity of PPARc
Experimental data have revealed the pivotal role exerted by
increased PPARc in positively modulating CD36 expression in
macrophages in response to diﬀerent stimuli such as oxLDL
[14,23] or cytokines [24]. Thus we evaluated whether the ob-
served up-regulation of CD36 in 3T3-L1 cells was somehow re-
lated to oxLDL eﬀects on PPARc activity. We widened our
previous data [6] regarding PPARc expression in oxLDL-trea-
ted cells. PPARc did not show the marked increase in mRNA
expression normally observed during adipocyte diﬀerentiation,
showing instead a signiﬁcant decrease on day 5 (30%;
P 6 0.05) and on day 7 (42%; P 6 0.05) with respect to un-
treated and nLDL-treated cells (Fig. 2A). Speciﬁcally, a signif-
icant decrease of the nuclear PPARc level was observed on day
7 (36%; P 6 0.05) in oxLDL-treated cells with respect to
time-matched controls (Fig. 2B). Furthermore, the decrease
in nuclear level was associated with a signiﬁcant reduction in
PPARc activity on day 5 (31%; P 6 0.05) and day 7
(40%; P 6 0.05) with respect to the time-matched controls
(Fig. 2C).
3.3. OxLDL activate Nrf2 in preadipocytes committed to
diﬀerentiate
Our ﬁndings on PPARc, and published data indicating Nrf2
as a novel signalling pathway involved in up-regulating CD36
expression in murine macrophages [16], led us to evaluate
whether the modulation of CD36 induced by oxLDL could
be aﬀected by Nrf2 activation. To this end we assessed the nu-
clear Nrf2 translocation that is required to regulate speciﬁcNrf2
Lamin B
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strong, transient up-regulation of nuclear Nrf2 level that was
detected 5 h after treatment with respect to control cells (1.8-
fold; P 6 0.01), and rapidly returned to basal level (Fig. 3).
A slight increase in Nrf2 was detected also in control cells,
probably due to the activity of dexamethasone contained in
DMIX [25], as suggested by the increase we found in cells trea-
ted with dexamethasone alone (data not shown).600
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To determine whether the activation of Nrf2 was respon-
sible for the increase in CD36 expression mediated by
oxLDL, we knocked down Nrf2 by short interfering RNA
(siRNA). OxLDL-treated cells transfected with the anti-
Nrf2-siRNA (but not with siRNA negative control), showed
a remarkable reduction of Nrf2 nuclear protein peak at 5 h
(85%; P 6 0.05) with respect to the untransfected oxLDL-
treated cells (Fig. 4A). Worth of note, as a consequence of
Nrf2 knockdown, CD36 protein signiﬁcantly decreased on
day 2 (43%; P 6 0.05) and day 5 (35%; P 6 0.05)
(Fig. 4B). These results clearly showed that CD36 over-
expression in oxLDL-treated cells was, at least partially,
Nrf2-dependent.0
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ig. 4. Eﬀects of anti-Nrf2-siRNA transfection on oxLDL-induced
D36 up-regulation in 3T3-L1 cells. Pre-conﬂuent preadipocytes were
ansfected with anti-Nrf2-siRNA (100 nM). Cells transfected with
rambled siRNA were used as negative control. Twenty-four hours
ter, oxLDL (50 mg protein/l) were added to transfected cells induced
diﬀerentiate. Western blot determination of nuclear Nrf2 protein
); CD36 protein (B). Values (means ± S.E.M.) are expressed as
ercentage with respect to day 0 (100%) (n = 3). *P 6 0.05, **P 6 0.01
xLDL-treated cells transfected with anti-Nrf2-siRNA (oxLDL + Si)
s. oxLDL-treated cells (oxLDL) within each time point considered.
epresentative blots are shown.3.5. Involvement of signalling kinases in Nrf2 nuclear
translocation
The phosphorylation of Nrf2 is considered the main mecha-
nism responsible for its activation and the consequent nuclear
translocation. Several signalling kinases have been suggested
to be involved in the regulation of Nrf2. Using speciﬁc inhib-
itors we investigated which of them were speciﬁcally involved.
The treatment of preadipocytes with SP600125 – a JNK inhib-
itor – did not alter the oxLDL-induced Nrf2 activation.
PD98059 (ERK1/2 inhibitor), SB203580 (p38) and LY294002
(PI3K), counteracted it only partially. Conversely, STS – a
PKC inhibitor – was capable to largely attenuate oxLDL-in-
duced Nrf2 increase (Fig. 5).
In agreement with reported evidence [17], our data suggested
that PKC was chieﬂy involved in phosphorylating Nrf2 and
triggering its nuclear translocation. To conﬁrm its involve-
ment, we studied PKC phosphorylation: oxLDL treatment
of preadipocytes resulted in the early phosphorylation of
PKC, which reached a three-fold increase after 10 min
(P 6 0.01), without aﬀecting total PKC expression (Fig. 6A).
Since it has been demonstrated that PKCd – implicated in a
number of cellular processes involving oxidative stress [26,27] –
is the isoform speciﬁcally involved in phosphorylating Nrf2
[17,28], we examined whether this isoform participated in
Nrf2 activation in our cells. We showed that oxLDL enhanced
phosphorylated-PKCd, which reached a 2.4-fold increase after
20 min (P 6 0.01), without aﬀecting total PKCd expression
(Fig. 6B).
Conversely, in control cells the phosphorylated forms of nei-
ther total PKC nor the delta isoform increased during the en-
tire experimental period (Fig. 6C and D). Furthermore, we
demonstrated that rottlerin – a speciﬁc PKCd inhibitor – coun-
teracted the Nrf2 increase in oxLDL-treated preadipocytes
(Fig. 7). PKCd appeared, therefore, largely responsible for
the activation of Nrf2, even if we cannot exclude that other iso-
forms could also be involved. Finally, we evaluated whether
the inhibition of PKC and PKCd aﬀected CD36 expression.Both the inhibitors strongly counteracted the increased expres-
sion of CD36 observed in oxLDL-treated cells on day 5
(Fig. 8), further conﬁrming the involvement of Nrf2 in CD36
up-regulation.4. Discussion
We have recently demonstrated that oxLDL inhibit preadi-
pocytes diﬀerentiation, altering adipose tissue homeostasis,
and that the membrane receptor CD36 mediates oxLDL ef-
fects, by allowing their internalization in preadipocytes [6].
Data herein reported, show for the ﬁrst time that oxLDL
strongly up-regulated CD36 expression in preadipocytes.
Several studies have shown that CD36 is a major regulator
of long-chain FA transport across the cell membrane in a vari-A
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expression in adipose tissue is associated with circulating glu-
cose and insulin concentrations as well as with Body Mass In-dex [32], it is still uncertain whether hyperinsulinemia,
hyperglycaemia and/or other may induce CD36 increase.
Besides being a FA transporter, CD36 acts as scavenger
receptor, the major receptor for oxLDL in macrophages [30].
Furthermore, CD36 has been previously demonstrated to
internalize oxLDL in adipocytes, suggesting that they can
function as phagocytes, like macrophages, and that might par-
ticipate in the clearance of circulating oxLDL [10].
An increased expression of CD36 represents a tract of the
phenotype of mature adipocyte and it could be due to PPARc
which is in fact highly expressed in diﬀerentiating preadipo-
cytes [31]. Likewise, oxLDL have been reported to induce
the up-regulation of CD36 in macrophages, depending on
PPARc activation [14,23]. Conversely, in oxLDL-treated pre-
adipocytes induced to diﬀerentiate, PPARc did not show the
marked up-regulation normally observed during adipogenesis
[31] which was, in fact, substantially inhibited [6]. Further-
more, even PPARc activity was signiﬁcantly impaired by
oxLDL. Nevertheless the up-regulation of CD36 was even
more pronounced in oxLDL-treated preadipocytes with re-
spect to the diﬀerentiating controls. These results suggested
that other signalling pathways might have been involved in
CD36 up-regulation in our cell system.
In macrophages oxLDL activate the transcription factor
Nrf2, which is an important regulator of CD36 expression
in these cells [15]. This ﬁnding, together with our data on
PPARc, prompted us to study the role of Nrf2 in CD36
over-expression induced by the oxidized lipoproteins in
3T3-L1 cells. To this end we evaluated the activation of
Nrf2 by determining its translocation to the nucleus, a nec-
essary event for Nrf2 to exert the regulatory eﬀects. Under
homeostatic conditions, Nrf2 is sequestered in the cytoplasm
by forming heterodimers with Kelch-like ECH-associated
protein 1 (Keap1) [32]. In the nucleus Nrf2 binds to antiox-
idant response elements (ARE) present in the promoter of
genes encoding antioxidant/detoxifying enzymes. It has been
hypothesized that Nrf2 represents a common way for acti-
vating cell defences in tissues, as rat adipose tissue [25], by
regulating also cell-speciﬁc target genes [33].
We showed that oxLDL induced a remarkable increase in
nuclear Nrf2 levels in preadipocytes with respect to control
cells. We thus hypothesized a close relationship between
the nuclear accumulation of Nrf2 and the observed up-regu-
lation of CD36 expression. Our hypothesis was strengthened
by the recent ﬁnding of multiple ARE-like sequences in the
promoter region of murine CD36 gene [15]. In order to fur-
ther conﬁrm our hypothesis we silenced Nrf2, demonstrating
that the transfected cells showed a marked reduction of nu-
clear Nrf2 level and, what is especially worth of note, this
decrease was accompanied by a signiﬁcant decrease of
CD36 protein.
Several studies have pointed out that phosphorylation repre-
sents the main mechanism for Nrf2 activation, since the phos-
phorylated form of Nrf2 shows a decreased aﬃnity for Keap1
and at the same time an increased stability against cytoplas-
matic degradation. Nrf2 phosphorylation can involve several
kinases [17,18,34]. Data collected from experiments with spe-
ciﬁc kinase inhibitors, suggested that PKC was the kinase
mainly involved in Nrf2 activation. In addition, it is worth not-
ing that the inhibition of PKC in oxLDL-treated cells not only
prevented the activation of Nrf2, but also inhibited the over-
expression of CD36. STS was, instead, ineﬀective in inhibiting
M. DArchivio et al. / FEBS Letters 582 (2008) 2291–2298 2297CD36 increase in control diﬀerentiating preadipocytes. Thus,
the CD36 up-regulation occurring in normal adipogenesis
could be determined by PPARc activity, while the increase ob-
served in cells subjected to a stress inducer – oxLDL in our
experimental system – might depend on the activated Nrf2
pathway.
Inactive cellular PKC – a family of serine/threonine phos-
photransferases – becomes fully activated by phosphorylation
[35]. In this regard, we demonstrated that oxLDL strongly in-
duced PKC phosphorylation very early before Nrf2 transloca-
tion. Although at present it is unclear which isoform(s) of PKC
is/are responsible for Nrf2 activation, a likely candidate seems
to be PKCd, implicated in a number of cellular processes
involving oxidative stress [36]. By treating the cells with the
speciﬁc inhibitor rottlerin, we demonstrated that PKCd was
particularly involved in oxLDL-induced activation of Nrf2.
Anyway, we cannot exclude that other isoforms could partici-
pate in this process. Furthermore, other signalling kinases such
as PI3K, p38 and ERK1/2 also were involved in Nrf2 nuclear
translocation, even though at a lesser extent. Further studies
should be thus addressed to clarify the eﬀective participation
of kinases in this process. Finally, we may not rule out the pos-
sibility that lipid peroxidation products, such as the unsatu-
rated aldehyde 4-HNE contained in the oxLDL, might
activate Nrf2 by directly modifying the thiol group in Keap1
protein.
In conclusion, our study provides novel evidence that
oxLDL induced CD36 over-expression in preadipocytes in a
PPARc-independent manner, and that Nrf2 played an essen-
tial role, mainly by the activation of the PKC signal transduc-
tion pathway. Since the Nrf2 pathway was responsible for this
up-regulation, we can hypothesize that, under stress condi-
tions, CD36 could act within the cellular defence system. In
adipocytes, the up-regulation of CD36 may indicate a compen-
sation mechanism to meet the demand of excessive oxLDL and
oxidised lipids in blood, reducing the risk of atherogenesis.
On the other hand, CD36 over-expression could be a poten-
tial marker of the metabolic syndrome – as suggested for the
soluble form of CD36 in insulin-resistant patients – although
its pathogenetic implications in insulin-resistance and diabetes
have not been elucidate yet [37].
Besides strengthening the hypothesis that oxLDL can con-
tribute to the appearance of insulin-resistance by altering adi-
pose tissue homeostasis and functionality, the data herein
presented highlight the signiﬁcance of oxLDL-induced CD36
over-expression within the cellular defence response.
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